Human metapneumovirus

Last updated
Human metapneumovirus
Pathogens-04-00682-g001.png
Human metapneumovirus (hMPV) structure and genome
Virus classification OOjs UI icon edit-ltr.svg
(unranked): Virus
Realm: Riboviria
Kingdom: Orthornavirae
Phylum: Negarnaviricota
Class: Monjiviricetes
Order: Mononegavirales
Family: Pneumoviridae
Genus: Metapneumovirus
Species:
Human metapneumovirus

Human metapneumovirus (HMPV or hMPV) is a negative-sense single-stranded RNA virus of the family Pneumoviridae [1] and is closely related to the Avian metapneumovirus (AMPV) subgroup C. It was isolated for the first time in 2001 in the Netherlands by using the RAP-PCR (RNA arbitrarily primed PCR) technique for identification of unknown viruses growing in cultured cells. [2] As of 2016, it was the second most common cause (after respiratory syncytial virus (RSV)) of acute respiratory tract illness in otherwise-healthy children under the age of 5 in a large US outpatient clinic. [3]

Contents

The peak age of hospitalization for infants with HMPV occurs between 6–12 months of age, slightly older than the peak of RSV, which is around 2–3 months. The clinical features and severity of HMPV are similar to those of RSV. HMPV is also an important cause of disease in older adults.

Taxonomy

Genus Metapneumovirus: species and their viruses [1] [4]
GenusSpeciesVirus (abbreviation)NCBI taxonomy ID
MetapneumovirusAvian metapneumovirusavian metapneumovirus (AMPV) 38525
Human metapneumovirushuman metapneumovirus (HMPV) 162145

Discovery and naming

Human metapneumovirus was first discovered in 2001 in the Netherlands by Bernadette G. van den Hoogen and her colleagues. [5] [6] [7] [8] hMPV was first detected in the respiratory secretions of 28 young children in the Netherlands and had initially stood out from other common respiratory viruses because the testing methods van den Hoogen et al. had tried using (immunological assays using virus-specific antibodies and PCR-based methods using virus genome-specific primers) were only able to test for known respiratory viruses and, therefore, were unable to identify the novel virus. [5] It was not until researchers began applying molecular biology techniques that the genetic characteristics and portions of the genomic sequences of the virus could be identified; these techniques included the randomly primed PCR technique which obtained the limited sequence data needed to reveal a clear relationship between this new virus and the avian pneumovirus. [5] It was this close relationship to AMPV that gave rise to this new virus being named human metapneumovirus [5] to reflect both its identity as a metapneumovirus and its use of humans as a host organism.

Epidemiology

HMPV was responsible for 12% of cases of acute respiratory tract illness in otherwise-healthy children in a US outpatient clinic [3] and 15% and 8% of cases (respectively) of community-acquired pneumonia requiring hospitalization in children under and over the age of 5 in the United States. [9] The virus is distributed worldwide and, in temperate regions, has a seasonal distribution generally following that of RSV and influenza virus during late winter and spring. [3] [10] Serologic studies have shown that by the age of five, virtually all children worldwide have been exposed to the virus. [2] [11] [12] [13] Despite near universal infection during early life, reinfections are common in older children and adults. [3] [14] [12] [15] Human metapneumovirus may cause mild upper respiratory tract infection (the common cold). However, premature infants, [16] immunocompromised persons, [17] [18] [19] [20] and older adults >65 years [15] [21] [22] are at risk for severe disease and hospitalization. In some studies of hospitalizations and emergency room visits, HMPV is nearly as common and as severe as influenza in older adults. [15] [21] [22] [23] HMPV is associated with more severe disease in people with asthma [24] [25] [26] [27] and adults with chronic obstructive pulmonary disease (COPD). [28] [29] [30] Numerous outbreaks of HMPV have been reported in long-term care facilities for children and adults, causing fatalities. [31] [32] [33] [34] [35]

Genome

The genomic organisation of HMPV is similar to RSV; however, HMPV lacks the non-structural genes, NS1 and NS2, and the HMPV antisense RNA genome contains eight open reading frames in slightly different gene order than RSV (viz. 3’-N-P-M-F-M2-SH-G-L-5’). [36] HMPV is genetically similar to the avian metapneumoviruses A, B and in particular type C. Phylogenetic analysis of HMPV has demonstrated the existence of two main genetic lineages termed subtype A and B containing within them the subgroups A1/A2 and B1/B2 respectively. Genotyping based on sequences of the F and G genes showed that subtype B was associated with increased cough duration and increased general respiratory systems compared to HMPV-A. [37]

Life cycle and reproduction

hMPV is estimated to have a 3–6 day incubation period and is often most active during the later winter and spring seasons in temperate climates, overlapping with the RSV and influenza seasons and possibly allowing for repeated infection. [6] But because it is still a relatively new virus and has not yet been researched very heavily, hMPV and its replication cycle still have a lot of mystery surrounding them. However, researchers have been able to elucidate some principal steps of hMPV's replication cycle, basing their approach and experimentation on the current knowledge we have of the viral life cycles and reproductive measures of the rest of the Paramyxoviridae family. [38]

With that being said, it has been determined that the first step of the hMPV replication cycle is attachment to the host cell, specifically the epithelial cells of the respiratory tract, using the G protein. [8] [38] This G protein contains a hydrophobic region that acts as an uncleaved signal peptide and a membrane anchor to facilitate its binding; however, because recombinant viruses that lack the G protein have still been able to replicate in vitro and in vivo, it seems that attachment via the G protein is not required for rest of the replication cycle. [8]

Next in the cycle is the fusion of the viral and host membranes which is likely mediated by the F protein. [8] [38] Though the fusion mechanism is very similar to that of other Paramyxoviridae family members and involves conformational changes of the F protein, the mechanism for hMPV does not depend on the G protein for fusion like its family members, showing consistency with the previously mentioned idea that the G protein is not necessary for subsequent steps of the hMPV replication cycle. [8] [38] Moreover, the fusion function of the F protein has been proven by its ability to bind to host cells via integrin αvβ1 using an Arginine-Glycine-Aspartate (RGD) motif, which is speculated to be the trigger for membrane fusion events. [8] One main difference between hMPV and other Paramyxoviridae viruses’ fusion mechanisms though is that hMPV's fusion events occur at acidic pH levels while other viruses’ fusion events occur at neutral pH levels; however, more research needs to be conducted in this area to get a better understanding of what is different about the hMPV fusion mechanism and why. [38] Although its specific function is uncertain, it is important to note the presence of the SH glycoprotein which seemingly does not have any effects on replication kinetics, cytopathic effects, or plaque formation of hMPV. [38]

After fusion, the viral ribonucleoprotein (RNP) containing negative-sense viral RNA (vRNA) genome is released into the cytoplasm and acts as a template for mRNA and antigenomic cRNA synthesis. [8] From here, most of our knowledge about hMPV transcription is derived from what we already know about RSV and other Paramyxoviridae viruses, including that leader and trailer sequences in the genome are partially complementary and act as promoters for transcription. [8] We see that proteins N, P, and L dissociate from the vRNA and bind to each other to form the polymerase complex so that the genomic RNA can act as a matrix for viral transcription and replication in the cytoplasm. [38] The final step in the replication process of hMPV that is relatively certain is the journeying of the envelope glycoproteins (F, G, and SH) to zones of membranous accumulation via the Golgi apparatus to be exposed at the surface of infected cells. [38] This allows infected cells to merge with adjacent cells through the action of viral fusion proteins on the surface, effectively spreading the virus's genome. [38] The rest of the replication cycle following RNA and viral protein synthesis are unclear and require further research. [8]

Virology

HMPV infects airway epithelial cells in the nose and lung. HMPV is thought to attach to the target cell via the glycoprotein (G) protein interactions with heparan sulfate and other glycosaminoglycans. The HMPV fusion (F) protein encodes an RGD (Arg-Gly-Asp) motif that engages RGD-binding integrins as cellular receptors, [39] [40] [41] [42] then mediates fusion of the cell membrane and viral envelope in a pH-independent fashion, likely within endosomes. [43] [44] HMPV then induces the response of chemokines and cytokines such as IL-6, IFN-alpha, TNF-alpha, IL-2, and macrophage inflammatory proteins, which in turn leads to peribronchiolar and perivascular infiltration and inflammation. [45]

Detection

The identification of HMPV has predominantly relied on reverse-transcriptase polymerase chain reaction (RT-PCR) technology to amplify directly from RNA extracted from respiratory specimens. Alternative more cost-effective approaches to the detection of HMPV by nucleic acid-based approaches have been employed and these include:

  1. detection of hMPV antigens in nasopharyngeal secretions by immunofluorescent-antibody test
  2. the use of immunofluorescence staining with monoclonal antibodies to detect HMPV in nasopharyngeal secretions and shell vial cultures
  3. immunofluorescence assays for detection of hMPV-specific antibodies
  4. the use of polyclonal antibodies and direct isolation in cultured cells.

Distribution and habitat

Though hMPV was first discovered and identified in 2001, serological studies showed that hMPV, or a close relative of it, had already been circulating for at least 50 years. [5] [46] From this information, it is clear that the virus had not just “jumped” from birds, or some other animal reservoir, to humans shortly before its discovery. [5]

So far, peak infection from hMPV in the northern hemisphere is in late winter and early spring, but it can be found globally across all continents [46] and its distribution is very complex and dynamic. [5] Researchers have found that hMPV is mostly localized and can differ significantly from community to community, allowing for the possibility of the strain in one location one year to be most similar to the strain in a different location the next year. [5] This phenomenon has actually been recorded with the virus strains in Australia in 2001; in France in 2000 and 2002; in Canada in 1999, 2000, 2001, and 2002; in Israel in 2002; and in the Netherlands in 2001 all being very closely related based on their F gene sequences. [5] There are at least two major genotypes of hMPV (A and B) that circulate during community outbreaks and each genotype has two of its own, [5] but as of now, it seems that no one strain is dominant over the others and none of them are known to cause varying levels of severity. [46]

hMPV is most likely spread from infected individuals to others through 1. secretions from coughing and sneezing, 2. close personal contact (ex. touching, shaking hands, etc), and 3. touching objects with viruses on them then touching your mouth, nose, or eyes. [6] Development of a reliable antiviral therapy treatment or vaccine to prevent the spread of hMPV has yet to occur, but there does seem to be promising developments in that area. [5] [6] In some vaccine trials, researchers have observed how a live recombinant human parainfluenza virus that contains the hMPV F gene can induce hMPV-specific antibodies and can protect experimental animals from hMPV. [5] Another similar study demonstrated how a chimeric bovine/human parainfluenza virus 3 expressing the hMPV F gene allows for neutralizing antibodies against both parainfluenza and hMPV. [5] However promising these results and trials may seem, it is important to note that these experiments have limitations including their small-population animal models. [5] Overall, while vaccines and antiviral therapy treatments are in the works, the biggest difficulty that researchers face at the moment is the limited data available about the development of hMPV in the natural host. [5]

Transmission

There are no conclusive studies to date; however, it is likely that transmission occurs by contact with contaminated secretions, via droplet, aerosol, or fomite vectors. Hospital-acquired infections with human metapneumovirus have been reported. [47] HMPV has been shown to circulate during fall and winter months with alternating predominance of a single subtype each year. [37]

Treatment

No treatment is yet known, [48] but ribavirin has shown effectiveness in an animal model. [49]

American pharmaceutical corporation Moderna has conducted a clinical trial for a candidate modRNA vaccine against metapneumovirus. [50] As of October 2019, the vaccine candidate has passed through phase I, with reports that the vaccine is well-tolerated at all dose levels at two months, and provokes an immune response which boosts the production of neutralising antibodies. [51]

Evolution

Human metapneumovirus was first reported in 2001 and avian metapneumovirus in the 1970s. There are at least four lineages of human metapneumovirus—A1, A2, B1 and B2. Avian metapneumovirus has been divided into four subgroups—A, B, C and D. Bayesian estimates suggest that human metapneumovirus emerged 119–133 years ago and diverged from avian metapneumovirus around 1800. [52]

Related Research Articles

<i>Rotavirus</i> Specific genus of RNA viruses

Rotaviruses are the most common cause of diarrhoeal disease among infants and young children. Nearly every child in the world is infected with a rotavirus at least once by the age of five. Immunity develops with each infection, so subsequent infections are less severe. Adults are rarely affected. Rotavirus is a genus of double-stranded RNA viruses in the family Reoviridae. There are nine species of the genus, referred to as A, B, C, D, F, G, H, I and J. Rotavirus A is the most common species, and these rotaviruses cause more than 90% of rotavirus infections in humans.

<span class="mw-page-title-main">Coronavirus</span> Subfamily of viruses in the family Coronaviridae

Coronaviruses are a group of related RNA viruses that cause diseases in mammals and birds. In humans and birds, they cause respiratory tract infections that can range from mild to lethal. Mild illnesses in humans include some cases of the common cold, while more lethal varieties can cause SARS, MERS and COVID-19. In cows and pigs they cause diarrhea, while in mice they cause hepatitis and encephalomyelitis.

<span class="mw-page-title-main">Respiratory syncytial virus</span> Species of a virus

Respiratory syncytial virus (RSV), also called human respiratory syncytial virus (hRSV) and human orthopneumovirus, is a contagious virus that causes infections of the respiratory tract. It is a negative-sense, single-stranded RNA virus. Its name is derived from the large cells known as syncytia that form when infected cells fuse.

<span class="mw-page-title-main">Rabies virus</span> Species of virus

Rabies virus, scientific name Rabies lyssavirus, is a neurotropic virus that causes rabies in animals, including humans. Rabies transmission can occur through the saliva of animals and less commonly through contact with human saliva. Rabies lyssavirus, like many rhabdoviruses, has an extremely wide host range. In the wild it has been found infecting many mammalian species, while in the laboratory it has been found that birds can be infected, as well as cell cultures from mammals, birds, reptiles and insects. Rabies is reported in more than 150 countries and on all continents except Antarctica. The main burden of disease is reported in Asia and Africa, but some cases have been reported also in Europe in the past 10 years, especially in returning travellers.

<span class="mw-page-title-main">Human parainfluenza viruses</span> Viruses that cause human parainfluenza

Human parainfluenza viruses (HPIVs) are the viruses that cause human parainfluenza. HPIVs are a paraphyletic group of four distinct single-stranded RNA viruses belonging to the Paramyxoviridae family. These viruses are closely associated with both human and veterinary disease. Virions are approximately 150–250 nm in size and contain negative sense RNA with a genome encompassing about 15,000 nucleotides.

<i>Human coronavirus NL63</i> Species of virus

Human coronavirus NL63 (HCoV-NL63) is a species of coronavirus, specifically a Setracovirus from among the Alphacoronavirus genus. It was identified in late 2004 in patients in the Netherlands by Lia van der Hoek and Krzysztof Pyrc using a novel virus discovery method VIDISCA. Later on the discovery was confirmed by the researchers from the Rotterdam, the Netherlands The virus is an enveloped, positive-sense, single-stranded RNA virus which enters its host cell by binding to ACE2. Infection with the virus has been confirmed worldwide, and has an association with many common symptoms and diseases. Associated diseases include mild to moderate upper respiratory tract infections, severe lower respiratory tract infection, croup and bronchiolitis.

<i>Jaagsiekte sheep retrovirus</i> Species of virus

Jaagsiekte sheep retrovirus (JSRV) is a betaretrovirus which is the causative agent of a contagious lung cancer in sheep, called ovine pulmonary adenocarcinoma.

Rous sarcoma virus (RSV) is a retrovirus and is the first oncovirus to have been described. It causes sarcoma in chickens.

<i>Murine respirovirus</i> Sendai virus, virus of rodents

Murine respirovirus, formerly Sendai virus (SeV) and previously also known as murine parainfluenza virus type 1 or hemagglutinating virus of Japan (HVJ), is an enveloped, 150-200 nm–diameter, negative sense, single-stranded RNA virus of the family Paramyxoviridae. It typically infects rodents and it is not pathogenic for humans or domestic animals.

Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections. It is recommended for infants at high-risk for RSV due to conditions such as prematurity or other medical problems including heart or lung diseases.

<span class="mw-page-title-main">Antibody-dependent enhancement</span> Antibodies rarely making an infection worse instead of better

Antibody-dependent enhancement (ADE), sometimes less precisely called immune enhancement or disease enhancement, is a phenomenon in which binding of a virus to suboptimal antibodies enhances its entry into host cells, followed by its replication. The suboptimal antibodies can result from natural infection or from vaccination. ADE may cause enhanced respiratory disease, but is not limited to respiratory disease. It has been observed in HIV, RSV virus and Dengue virus and is monitored for in vaccine development.

As of 2024, a vaccine against Epstein–Barr virus was not yet available. The virus establishes latent infection and causes infectious mononucleosis. There is also increasingly more evidence that EBV may be a trigger of multiple sclerosis. It is a dual-tropic virus, meaning that it infects two different host cell types — in this case, both B cells and epithelial cells. One challenge is that the Epstein–Barr virus expresses very different proteins during its lytic and its latent phases. Antiviral agents act by inhibiting viral DNA replication, but as of 2016, there was little evidence that they are effective against Epstein–Barr virus, they are expensive, they risk causing resistance to antiviral agents, and can cause unpleasant side effects.

Avian metapneumovirus (aMPV), also known as turkey rhinotracheitis or swollen head syndrome, causes a variety of disease syndromes in birds, depending on the bird species and virus type.

<i>Human coronavirus HKU1</i> Species of virus

Human coronavirus HKU1 (HCoV-HKU1) is a species of coronavirus in humans and animals. It causes an upper respiratory disease with symptoms of the common cold, but can advance to pneumonia and bronchiolitis. It was first discovered in January 2004 from one man in Hong Kong. Subsequent research revealed it has global distribution and earlier genesis.

<i>Monkeypox virus</i> Species of double-stranded DNA virus

The monkeypox virus, is a species of double-stranded DNA virus that causes mpox disease in humans and other mammals. The monkeypox virus is a zoonotic virus belonging to the orthopoxvirus genus, making it closely related to the variola, cowpox, and vaccinia viruses. MPV is oval-shaped with a lipoprotein outer membrane. The genome is approximately 190 kb.

<i>Pneumoviridae</i> Family of viruses

Pneumoviridae is a family of negative-strand RNA viruses in the order Mononegavirales. Humans, cattle, and rodents serve as natural hosts. Respiratory tract infections are associated with member viruses such as human respiratory syncytial virus. There are five species in the family which are divided between the genera Metapneumovirus and Orthopneumovirus. The family used to be considered as a sub-family of Paramyxoviridae, but has been reclassified as of 2016.

Ghanaian bat henipavirus (also known Kumasi virus belongs to the genus Henipavirus in the family Paramyxoviridae. Human infections are caused by zoonotic events where the virus crosses over from another animal species. Therefore, humans are not the innate host for this virus family but instead become infected by peripheral viral reservoirs such as bats and other carriers of the virus. When these virus are spread to humans through zoonotic events they have been found to be one of the most deadly viruses with the capability to infect humans, with mortality rates between 50 and 100%. Therefore, these viruses have been classified as a biosafety level four virus with regards to its pathogenesis when it infects humans.

<span class="mw-page-title-main">Presatovir</span> Chemical compound

Presatovir (GS-5806) is an antiviral drug which was developed as a treatment for respiratory syncytial virus. It acts as a fusion inhibitor, and has shown promising results in Phase II clinical trials.

<span class="mw-page-title-main">Lumicitabine</span> Chemical compound

Lumicitabine (ALS-8176) is an antiviral drug which was developed as a treatment for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). It acts as an RNA polymerase inhibitor. While it showed promise in early clinical trials, poor results in Phase IIb trials led to it being discontinued from development for treatment of RSV. Research continues to determine whether it may be useful for the treatment of diseases caused by other RNA viruses, and it has been found to show activity against Nipah virus.

<span class="mw-page-title-main">Viral vector vaccine</span> Type of vaccine

A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material (DNA) that can be transcribed by the recipient's host cells as mRNA coding for a desired protein, or antigen, to elicit an immune response. As of April 2021, six viral vector vaccines, four COVID-19 vaccines and two Ebola vaccines, have been authorized for use in humans.

References

  1. 1 2 "ICTV Online (10th) Report".
  2. 1 2 van den Hoogen, Bernadette G.; Jong, Jan C. de; Groen, Jan; Kuiken, Thijs; Groot, Ronald de; Fouchier, Ron A.M.; Osterhaus, Albert D.M.E. (2001). "A newly discovered human pneumovirus isolated from young children with respiratory tract disease". Nature Medicine. 7 (6): 719–724. doi:10.1038/89098. PMC   7095854 . PMID   11385510.
  3. 1 2 3 4 Williams, John V.; Harris, Paul A.; Tollefson, Sharon J.; Halburnt-Rush, Lisa L.; Pingsterhaus, Joyce M.; Edwards, Kathryn M.; Wright, Peter F.; Crowe, James E. Jr. (2004-01-29). "Human Metapneumovirus and Lower Respiratory Tract Disease in Otherwise Healthy Infants and Children". New England Journal of Medicine. 350 (5): 443–450. doi:10.1056/nejmoa025472. ISSN   0028-4793. PMC   1831873 . PMID   14749452.
  4. ↑ Amarasinghe, Gaya K.; Bào, Yīmíng; Basler, Christopher F.; Bavari, Sina; Beer, Martin; Bejerman, Nicolás; Blasdell, Kim R.; Bochnowski, Alisa; Briese, Thomas (2017-04-07). "Taxonomy of the order Mononegavirales: update 2017". Archives of Virology. 162 (8): 2493–2504. doi:10.1007/s00705-017-3311-7. PMC   5831667 . PMID   28389807.
  5. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Kahn, Jeffrey S. (July 2006). "Epidemiology of Human Metapneumovirus". Clinical Microbiology Reviews. 19 (3): 546–557. doi:10.1128/cmr.00014-06. PMC   1539100 . PMID   16847085.
  6. 1 2 3 4 "Human Metapneumovirus". Centers for Disease Control and Prevention. 13 April 2023.
  7. ↑ "Human Metapneumovirus (HMPV): Causes & Treatment". Cleveland Clinic.
  8. 1 2 3 4 5 6 7 8 9 Schildgen, Verena; Van Den Hoogen, Bernadette; Fouchier, Ron; Tripp, Ralph A.; Alvarez, Rene; Manoha, Catherine; Williams, John; Schildgen, Oliver (Oct 2011). "Human Metapneumovirus: Lessons Learned over the First Decade". Clinical Microbiology Reviews. 24 (4): 734–754. doi:10.1128/cmr.00015-11. PMC   3194831 . PMID   21976607.
  9. ↑ Jain, Seema; Williams, Derek J.; Arnold, Sandra R.; Ampofo, Krow; Bramley, Anna M.; Reed, Carrie; Stockmann, Chris; Anderson, Evan J.; Grijalva, Carlos G. (2015-02-25). "Community-Acquired Pneumonia Requiring Hospitalization among U.S. Children". New England Journal of Medicine. 372 (9): 835–845. doi:10.1056/nejmoa1405870. PMC   4697461 . PMID   25714161.
  10. ↑ Williams, John V.; Wang, Chiaoyin K.; Yang, Chin-Fen; Tollefson, Sharon J.; House, Frances S.; Heck, Josh M.; Chu, Marla; Brown, Jennifer B.; Lintao, Linda D. (2006-02-01). "The Role of Human Metapneumovirus in Upper Respiratory Tract Infections in Children: A 20-Year Experience". The Journal of Infectious Diseases. 193 (3): 387–395. doi:10.1086/499274. ISSN   0022-1899. PMC   1586246 . PMID   16388486.
  11. ↑ Leung, Jessica; Esper, Frank; Weibel, Carla; Kahn, Jeffrey S. (2005-03-01). "Seroepidemiology of Human Metapneumovirus (hMPV) on the Basis of a Novel Enzyme-Linked Immunosorbent Assay Utilizing hMPV Fusion Protein Expressed in Recombinant Vesicular Stomatitis Virus". Journal of Clinical Microbiology. 43 (3): 1213–1219. doi:10.1128/jcm.43.3.1213-1219.2005. ISSN   0095-1137. PMC   1081231 . PMID   15750086.
  12. 1 2 Pavlin, Julie A.; Hickey, Andrew C.; Ulbrandt, Nancy; Chan, Yee-Peng; Endy, Timothy P.; Boukhvalova, Marina S.; Chunsuttiwat, Supamit; Nisalak, Ananda; Libraty, Daniel H. (2008-09-15). "Human Metapneumovirus Reinfection among Children in Thailand Determined by ELISA Using Purified Soluble Fusion Protein". The Journal of Infectious Diseases. 198 (6): 836–842. doi:10.1086/591186. ISSN   0022-1899. PMC   2648801 . PMID   18680407.
  13. ↑ Dunn, Sarah R.; Ryder, Alex B.; Tollefson, Sharon J.; Xu, Meng; Saville, Benjamin R.; Williams, John V. (2013-10-01). "Seroepidemiologies of Human Metapneumovirus and Respiratory Syncytial Virus in Young Children, Determined with a New Recombinant Fusion Protein Enzyme-Linked Immunosorbent Assay". Clinical and Vaccine Immunology. 20 (10): 1654–1656. doi:10.1128/cvi.00750-12. ISSN   1556-6811. PMC   3807191 . PMID   23945161.
  14. ↑ Howard, Leigh M.; Edwards, Kathryn M.; Zhu, Yuwei; Griffin, Marie R.; Weinberg, Geoffrey A.; Szilagyi, Peter G.; Staat, Mary A.; Payne, Daniel C.; Williams, John V. (2017). "Clinical Features of Human Metapneumovirus Infection in Ambulatory Children Aged 5–13 Years". Journal of the Pediatric Infectious Diseases Society. 7 (2): 165–168. doi:10.1093/jpids/pix012. PMC   5954304 . PMID   28369564.
  15. 1 2 3 Falsey, Ann R.; Erdman, Dean; Anderson, Larry J.; Walsh, Edward E. (2003-03-01). "Human Metapneumovirus Infections in Young and Elderly Adults". The Journal of Infectious Diseases. 187 (5): 785–790. doi: 10.1086/367901 . ISSN   0022-1899. PMID   12599052.
  16. ↑ Williams, John V.; Maitre, Nathalie (2016-07-28). "Human metapneumovirus in the preterm neonate: current perspectives". Research and Reports in Neonatology. 6: 41–49. doi: 10.2147/rrn.s76270 . PMC   5120728 . PMID   27891060.
  17. ↑ Shahda, S.; Carlos, W.g.; Kiel, P.j.; Khan, B.a.; Hage, C.a. (2011-06-01). "The human metapneumovirus: a case series and review of the literature". Transplant Infectious Disease. 13 (3): 324–328. doi:10.1111/j.1399-3062.2010.00575.x. ISSN   1399-3062. PMC   3107511 . PMID   21631655.
  18. ↑ Chu, Helen Y.; Renaud, Christian; Ficken, Elle; Thomson, Blythe; Kuypers, Jane; Englund, Janet A. (2014-12-01). "Respiratory Tract Infections Due to Human Metapneumovirus in Immunocompromised Children". Journal of the Pediatric Infectious Diseases Society. 3 (4): 286–293. doi:10.1093/jpids/piu100. ISSN   2048-7193. PMC   4240341 . PMID   25419459.
  19. ↑ Seo, Sachiko; Gooley, Ted A.; Kuypers, Jane M.; Stednick, Zachary; Jerome, Keith R.; Englund, Janet A.; Boeckh, Michael (2016-07-15). "Human Metapneumovirus Infections Following Hematopoietic Cell Transplantation: Factors Associated With Disease Progression". Clinical Infectious Diseases. 63 (2): 178–185. doi:10.1093/cid/ciw284. ISSN   1058-4838. PMC   4928387 . PMID   27143659.
  20. ↑ Shah, Dimpy P.; Shah, Pankil K.; Azzi, Jacques M.; Chaer, Firas El; Chemaly, Roy F. (2016). "Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review". Cancer Letters. 379 (1): 100–106. doi:10.1016/j.canlet.2016.05.035. PMC   4935561 . PMID   27260872.
  21. 1 2 Walsh, Edward E.; Peterson, Derick R.; Falsey, Ann R. (2008-12-08). "Human Metapneumovirus Infections in Adults: Another Piece of the Puzzle". Archives of Internal Medicine. 168 (22): 2489–2496. doi:10.1001/archinte.168.22.2489. ISSN   0003-9926. PMC   2783624 . PMID   19064834.
  22. 1 2 Widmer, Kyle; Zhu, Yuwei; Williams, John V.; Griffin, Marie R.; Edwards, Kathryn M.; Talbot, H. Keipp (2012-07-01). "Rates of Hospitalizations for Respiratory Syncytial Virus, Human Metapneumovirus, and Influenza Virus in Older Adults". The Journal of Infectious Diseases. 206 (1): 56–62. doi:10.1093/infdis/jis309. ISSN   0022-1899. PMC   3415933 . PMID   22529314.
  23. ↑ Widmer, Kyle; Griffin, Marie R.; Zhu, Yuwei; Williams, John V.; Talbot, H. Keipp (2014-05-01). "Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults". Influenza and Other Respiratory Viruses. 8 (3): 347–352. doi:10.1111/irv.12234. ISSN   1750-2659. PMC   3984605 . PMID   24512531.
  24. ↑ Williams, John V.; Crowe, James E.; Enriquez, Rachel; Minton, Patricia; Peebles, R. Stokes; Hamilton, Robert G.; Higgins, Stanley; Griffin, Marie; Hartert, Tina V. (2005-10-01). "Human Metapneumovirus Infection Plays an Etiologic Role in Acute Asthma Exacerbations Requiring Hospitalization in Adults". The Journal of Infectious Diseases. 192 (7): 1149–1153. doi:10.1086/444392. ISSN   0022-1899. PMC   1476781 . PMID   16136455.
  25. ↑ Williams, John V.; Tollefson, Sharon J.; Heymann, Peter W.; Carper, Holliday T.; Patrie, James; Crowe Jr., James E. (2005). "Human metapneumovirus infection in children hospitalized for wheezing". Journal of Allergy and Clinical Immunology. 115 (6): 1311–1312. doi:10.1016/j.jaci.2005.02.001. PMC   1476700 . PMID   15940152.
  26. ↑ García-García, M.l.; Calvo, C.; Casas, I.; Bracamonte, T.; Rellán, A.; Gozalo, F.; Tenorio, T.; Pérez-Breña, P. (2007-05-01). "Human metapneumovirus bronchiolitis in infancy is an important risk factor for asthma at age 5". Pediatric Pulmonology. 42 (5): 458–464. doi:10.1002/ppul.20597. ISSN   1099-0496. PMID   17427899. S2CID   2395811.
  27. ↑ Khetsuriani, Nino; Kazerouni, N. Neely; Erdman, Dean D.; Lu, Xiaoyan; Redd, Stephen C.; Anderson, Larry J.; Teague, W. Gerald (2007). "Prevalence of viral respiratory tract infections in children with asthma". Journal of Allergy and Clinical Immunology. 119 (2): 314–321. doi:10.1016/j.jaci.2006.08.041. PMC   7112359 . PMID   17140648.
  28. ↑ Vicente, Diego; Montes, Milagrosa; Cilla, Gustavo; Pérez-Trallero, Emilio (July 2004). "Human Metapneumovirus and Chronic Obstructive Pulmonary Disease". Emerging Infectious Diseases. 10 (7): 1338–1339. doi:10.3201/eid1007.030633. ISSN   1080-6040. PMC   3323314 . PMID   15338546.
  29. ↑ Martinello, Richard A.; Esper, Frank; Weibel, Carla; Ferguson, David; Landry, Marie L.; Kahn, Jeffrey S. (2006). "Human metapneumovirus and exacerbations of chronic obstructive pulmonary disease". Journal of Infection. 53 (4): 248–254. doi:10.1016/j.jinf.2005.11.010. PMC   7112509 . PMID   16412516.
  30. ↑ Kan-o, Keiko; Ramirez, Ruben; MacDonald, Martin I.; Rolph, Michael; Rudd, Penny A.; Spann, Kirsten M.; Mahalingam, Suresh; Bardin, Philip G.; Thomas, Belinda J. (2017-05-15). "Human Metapneumovirus Infection in Chronic Obstructive Pulmonary Disease: Impact of Glucocorticosteroids and Interferon". The Journal of Infectious Diseases. 215 (10): 1536–1545. doi: 10.1093/infdis/jix167 . ISSN   0022-1899. PMID   28379462.
  31. ↑ Boivin, Guy; Serres, Gaston De; Hamelin, Marie-Eve; Côté, Stéphanie; Argouin, Marco; Tremblay, Geneviève; Maranda-Aubut, Renée; Sauvageau, Chantal; Ouakki, Manale (2007-05-01). "An Outbreak of Severe Respiratory Tract Infection Due to Human Metapneumovirus in a Long-Term Care Facility". Clinical Infectious Diseases. 44 (9): 1152–1158. doi: 10.1086/513204 . ISSN   1058-4838. PMID   17407031.
  32. ↑ Louie, Janice K.; Schnurr, David P.; Pan, Chao-Yang; Kiang, David; Carter, Connie; Tougaw, Sandra; Ventura, Jean; Norman, Agnes; Belmusto, Vivian (2007-09-01). "A Summer Outbreak of Human Metapneumovirus Infection in a Long-Term-Care Facility". The Journal of Infectious Diseases. 196 (5): 705–708. doi: 10.1086/519846 . ISSN   0022-1899. PMID   17674312.
  33. ↑ Neu, Natalie; Plaskett, Theresa; Hutcheon, Gordon; Murray, Meghan; Southwick, Karen L.; Saiman, Lisa (June 2012). "Epidemiology of Human Metapneumovirus in a Pediatric Long-Term Care Facility". Infection Control & Hospital Epidemiology. 33 (6): 545–550. doi:10.1086/665727. ISSN   0899-823X. PMID   22561708. S2CID   2132679.
  34. ↑ "Outbreaks of Human Metapneumovirus in Two Skilled Nursing Facilities — West Virginia and Idaho, 2011–2012". www.cdc.gov. Retrieved 2017-09-16.
  35. ↑ Yang, Zifeng; Suzuki, Akira; Watanabe, Oshi; Okamoto, Michiko; Ohmi, Akira; Huang, Wenbo; Nishimura, Hidekazu (2014). "Outbreak of human metapneumovirus infection in a severe motor-and-intellectual disabilities ward in Japan". Japanese Journal of Infectious Diseases. 67 (4): 318–321. doi: 10.7883/yoken.67.318 . ISSN   1884-2836. PMID   25056083.
  36. ↑ van den Hoogen, Bernadette G.; Bestebroer, Theo M.; Osterhaus, Albert D. M. E.; Fouchier, Ron A. M. (2002-03-30). "Analysis of the genomic sequence of a human metapneumovirus". Virology. 295 (1): 119–132. doi:10.1006/viro.2001.1355. hdl: 1765/3864 . ISSN   0042-6822. PMID   12033771.
  37. 1 2 Perchetti, GA; Wilcox, N; Chu, HY; Katz, J; Khatry, SK; LeClerq, SC; Tielsch, JM; Jerome, KR; Englund, JA; Kuypers, J (November 2020). "Human Metapneumovirus Infection and Genotyping of Infants in Rural Nepal". Journal of the Pediatric Infectious Diseases Society. 10 (4): 408–416. doi:10.1093/jpids/piaa118. PMID   33137178.
  38. 1 2 3 4 5 6 7 8 9 Feuillet, F.; Lina, B.; Rosa-Calatrava, M.; Boivin, G. (Feb 2012). "Ten years of human metapneumovirus research". Journal of Clinical Virology. 53 (2): 97–105. doi:10.1016/j.jcv.2011.10.002. PMID   22074934.
  39. ↑ Cseke, G.; Maginnis, M. S.; Cox, R. G.; Tollefson, S. J.; Podsiad, A. B.; Wright, D. W.; Dermody, T. S.; Williams, J. V. (2009). "Integrin  v 1 promotes infection by human metapneumovirus". Proceedings of the National Academy of Sciences. 106 (5): 1566–1571. doi: 10.1073/pnas.0801433106 . PMC   2629439 . PMID   19164533.
  40. ↑ Chang, A.; Masante, C.; Buchholz, U. J.; Dutch, R. E. (2012). "Human Metapneumovirus (HMPV) Binding and Infection Are Mediated by Interactions between the HMPV Fusion Protein and Heparan Sulfate". Journal of Virology. 86 (6): 3230–3243. doi:10.1128/JVI.06706-11. PMC   3302303 . PMID   22238303.
  41. ↑ Cox, R. G.; Livesay, S. B.; Johnson, M.; Ohi, M. D.; Williams, J. V. (2012). "The Human Metapneumovirus Fusion Protein Mediates Entry via an Interaction with RGD-Binding Integrins". Journal of Virology. 86 (22): 12148–12160. doi:10.1128/JVI.01133-12. PMC   3486500 . PMID   22933271.
  42. ↑ Wei, Y.; Zhang, Y.; Cai, H.; Mirza, A. M.; Iorio, R. M.; Peeples, M. E.; Niewiesk, S.; Li, J. (2014). "Roles of the Putative Integrin-Binding Motif of the Human Metapneumovirus Fusion (F) Protein in Cell-Cell Fusion, Viral Infectivity, and Pathogenesis". Journal of Virology. 88 (8): 4338–4352. doi:10.1128/JVI.03491-13. PMC   3993731 . PMID   24478423.
  43. ↑ Schowalter, R. M.; Smith, S. E.; Dutch, R. E. (2006). "Characterization of Human Metapneumovirus F Protein-Promoted Membrane Fusion: Critical Roles for Proteolytic Processing and Low pH". Journal of Virology. 80 (22): 10931–10941. doi:10.1128/JVI.01287-06. PMC   1642150 . PMID   16971452.
  44. ↑ Cox, Reagan G.; Mainou, Bernardo A.; Johnson, Monika; Hastings, Andrew K.; Schuster, Jennifer E.; Dermody, Terence S.; Williams, John V. (2015). "Human Metapneumovirus is Capable of Entering Cells by Fusion with Endosomal Membranes". PLOS Pathogens. 11 (12): e1005303. doi: 10.1371/journal.ppat.1005303 . PMC   4667933 . PMID   26629703.
  45. ↑ Uddin, Sanaa; Thomas, Meagan (2023), "Human Metapneumovirus", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID   32809745 , retrieved 2023-11-18
  46. 1 2 3 Uddin, Sanaa; Thomas, Meagan (July 18, 2022). "Human Metapneumovirus". StatPearls [Internet]. PMID   32809745.
  47. ↑ Peiris, JS; Tang, WH; Chan, KH; Khong, PL; Guan, Y; Lau, YL; Chiu, SS (June 2003). "Children with respiratory disease associated with metapneumovirus in Hong Kong". Emerging Infectious Diseases. 9 (6): 628–633. doi:10.3201/eid0906.030009. PMC   3000155 . PMID   12781000.
  48. ↑ Bao X, Liu T, Shan Y, Li K, Garofalo RP, Casola A (May 2008). Baric RS (ed.). "Human Metapneumovirus Glycoprotein G Inhibits Innate Immune Responses". PLOS Pathog. 4 (5): e1000077. doi: 10.1371/journal.ppat.1000077 . PMC   2386556 . PMID   18516301.
  49. ↑ Deffrasnes C, Hamelin ME, Boivin G (April 2007). "Human metapneumovirus". Semin Respir Crit Care Med. 28 (2): 213–21. doi:10.1055/s-2007-976493. PMID   17458775. S2CID   21308968.
  50. ↑ https://trials.modernatx.com/trials/NCT03392389 [ dead link ]
  51. ↑ "Moderna to Present Data from Two of Its Prophylactic mRNA Vaccines at IDWeek 2019" (Press release). 2 October 2019.
  52. ↑ de Graaf M, Osterhaus AD, Fouchier RA, Holmes EC (2008). "Evolutionary dynamics of human and avian metapneumoviruses". J. Gen. Virol. 89 (Pt 12): 2933–42. doi: 10.1099/vir.0.2008/006957-0 . PMID   19008378.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.